UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

14 New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

Read More Share:

Sep

30 UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

Read More Share:

Jun

12 UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024

Read More Share:

May

06 Evolving Expectations for Arthritis Management

Read More Share:

Nov

09 Advancing Rheumatic Disease Treatment

Read More Share:

Dec

07 The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

Read More Share:

May

23 UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

Read More Share:

May

12 Recognizing the Less Common, but Equally Burdensome, Forms of Arthritis During Arthritis Awareness Month

Read More Share:

Jan

21 Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

Read More Share:

Nov

19 Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms

Read More Share:

Categories

Archives

Nov

14

New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

Sep

30

UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

Jun

12

UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024

May

06

Evolving Expectations for Arthritis Management

Nov

09

Advancing Rheumatic Disease Treatment

Dec

07

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

May

23

UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

May

12

Recognizing the Less Common, but Equally Burdensome, Forms of Arthritis During Arthritis Awareness Month

Jan

21

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

Nov

19

Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Nov

14

New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

Sep

30

UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

Jun

12

UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024

May

06

Evolving Expectations for Arthritis Management

Nov

09

Advancing Rheumatic Disease Treatment

Dec

07

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

May

23

UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

May

12

Recognizing the Less Common, but Equally Burdensome, Forms of Arthritis During Arthritis Awareness Month

Jan

21

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

Nov

19

Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact